Pfizer Inc. (PFE)
Pfizer Post Loss on Higher Revenue
Pfizer swung to a second-quarter loss but posted higher revenue, as market growth in its oncology business offset some declines in its Covid-19 products.
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing the stronger-than-expected performance of non-Covid products. The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares to a previous outlook of $59.5 billion to $62.5 billion.
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
Pfizer's Bear Case Is Breaking
Pfizer's non-COVID commercial portfolio is accelerating, with new launches and business development products growing 22% to a nearly $12 billion annualized run rate. Seagen's oncology portfolio expanded 20% while Biohaven's migraine franchise surged 41%, demonstrating strong commercial momentum beyond the COVID business. COVID revenue is expected to decline from $11 billion in 2024 to approximately $5 billion in 2026, increasing reliance on newer growth drivers.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer: Still Mispriced By Mr. Market (Earnings Preview)
Pfizer remains a Buy, with a 16% nominal upside and ~7% dividend yield, driven by a diversified, expanding product portfolio. PFE's new growth portfolio, cost controls, and business reorganization are offsetting LOEs and COVID-related sales declines, supporting forward EPS stability. Upcoming Q2 earnings are expected to beat conservative consensus, with management updates on pipeline and product launches as key catalysts.
Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials
Pfizer said on Thursday its oral drug helped restore skin color in patients with a common form of vitiligo in two late-stage trials, paving the way for regulatory submissions seeking approval in the autoimmune skin disease.
Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?
Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far
I initiate Pfizer with a contrarian BUY rating and a $32 price target for 2026 Q3-Q4. PFE's non-COVID portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth despite patent cliffs. Padcev's July 2026 approval expands its addressable market, while pipeline assets like Berobenatide and PF-08634404 offer additional upside.
